Airway microbial and metabolic features associated with ICS therapy in COPD
Our findings suggest that ICS therapy not only reshapes the airway microbial ecosystem but also alters host-microbe co-metabolic pathways, particularly caffeine metabolism. By reducing microbial degradation of methylxanthines, ICS may enhance the bioavailability of bronchodilatory compounds, providing a potential microbiome-mediated adjunctive mechanism of action. These insights advance our understanding of ICS pharmacology in COPD and highlight the therapeutic potential of targeting microbiome-metabolite interactions.
Authors
- Hao Hu (ORCID: https://orcid.org/0000-0001-9441-106X)
- Xiaohua Du (ORCID: https://orcid.org/0000-0003-1777-024X)
- Xun Luo (ORCID: https://orcid.org/0000-0003-0244-9832)
- Lijun Chen (ORCID: https://orcid.org/0000-0001-9374-6466)
- Mei Yang (ORCID: https://orcid.org/0009-0008-2713-243X)
- Hongxia Yu
- Yan Tang (ORCID: https://orcid.org/0000-0002-9866-1098)
- Qixin Wang (ORCID: https://orcid.org/0000-0001-9051-8388)
Institutions
- Deyang Stomatological Hospital (CN)
- Dazhou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.3389/fphar.2025.1714879
- Citations
- 1
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Health Commission of Sichuan Province